CJC-1295 and TB-500

Mentioned together

Named together in the same review articles, never tested together. This page says that plainly and shows why researchers list them side by side.

How the two mechanisms relate

Neutral. TB-500, a thymosin beta-4 fragment, and CJC-1295, a GHRH analogue, are named together in research reviews but act on unrelated pathways, with no combined data recorded here.

This reading describes mechanism and is editorial. The grade above is the published record.

The compounds

CJC-1295

A long-acting GHRH analogue studied for growth-hormone release. Two early human trials measured hormone levels; no human study here reports a functional outcome.

Full profile, dosing and safety →

TB-500

A short fragment of thymosin beta-4. Almost all outcome data are animal or laboratory, and the one human randomized trial used the full parent peptide, not the fragment.

Full profile, dosing and safety →

Check these in the interaction tool →